| abstract |
Disclosed is a stabilized pharmaceutical composition having an aqueous solution having a pH of 8 to 10 inhibiting cholesterol biosynthesis comprising 0.5 to 60% by weight based on the total weight of the composition of the HMG-CoA reductase compound selected from the group consisting of sodium salt R * S * - (E) - (+ -) - 7- [3- (4-Fluorophenyl) -1- (1-methylethyl) -1H-indol-2-yl] -3,5-dihydroxy-6 -heptenic acid, sodium salt of 3R, 5S- (E) -7- [4- (4-fluorophenyl) -6- (1-methylethyl) -2-dimethylaminopyrimidin-5-yl] -3,5-dihydroxy-6- heptenic acid and sodium erythro - (+ -) - (E) -7- [3- (4-fluorophenyl) spiro [cyclopentane-1,1'-1H-inden] -2'-yl] -3, 5-dihydroxy-6-heptenic acid, and 0.1 to 60% by weight based on the total weight of the composition, alkali of the alkali and alkaline earth metal carbonates and bicarbonates, and, as the remainder, a pharmaceutically acceptable carrier or excipient. |